NEW YORK (GenomeWeb News) – InforSense said on Friday that GlaxoSmithKline has signed a contract to continue using the firm’s InforSense platform for another three years.
The London-based firm said that around 800 users within the drug giant are currently using the platform, which is a workflow-management software tool.
Terms of the deal were not disclosed.